Cargando…

Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells

Cancer stem cells (CSCs) can induce recurrence and chemotherapy resistance of lung adenocarcinoma (LUAD). Reliable markers identified based on CSC characteristic of LUAD may improve patients' chemotherapy response and prognosis. OCLR was used to calculate mRNA expression-based stemness index (m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Renping, Liao, Hongliang, Liu, Jingting, Zhou, Lin, Yin, Yingqiu, Mu, Tianhao, Wei, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036162/
https://www.ncbi.nlm.nih.gov/pubmed/35480140
http://dx.doi.org/10.1155/2022/4404406
_version_ 1784693463664558080
author Wan, Renping
Liao, Hongliang
Liu, Jingting
Zhou, Lin
Yin, Yingqiu
Mu, Tianhao
Wei, Jie
author_facet Wan, Renping
Liao, Hongliang
Liu, Jingting
Zhou, Lin
Yin, Yingqiu
Mu, Tianhao
Wei, Jie
author_sort Wan, Renping
collection PubMed
description Cancer stem cells (CSCs) can induce recurrence and chemotherapy resistance of lung adenocarcinoma (LUAD). Reliable markers identified based on CSC characteristic of LUAD may improve patients' chemotherapy response and prognosis. OCLR was used to calculate mRNA expression-based stemness index (mRNAsi) of LUAD patients' data in TCGA. Association analysis of mRNAsi was performed with clinical features, somatic mutation, and tumor immunity. A prognostic prediction model was established with LASSO Cox regression. Kaplan-Meier Plotter (KM-plotter) and time-dependent ROC were applied to assess signature performance. For LUAD, univariate and multivariate Cox analysis was performed to identify independent prognostic factors. LUAD tissues showed a noticeably higher mRNAsi in than nontumor tissues, and it showed significant differences in T, N, M, AJCC stages, and smoking history. The most frequently mutated gene was TP53, with a higher mRNAsi relating to more frequent mutation of TP53. The mRNAsi was significantly negatively correlated with immune score, stromal score, and ESTIMATE score in LUAD. The blue module was associated with mRNAsi. The 5-gene signature was confirmed as an independent indicator of LUAD prognosis that could promote personalized treatment of LUAD and accurately predict overall survival (OS) of LUAD patients.
format Online
Article
Text
id pubmed-9036162
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90361622022-04-26 Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells Wan, Renping Liao, Hongliang Liu, Jingting Zhou, Lin Yin, Yingqiu Mu, Tianhao Wei, Jie Biomed Res Int Research Article Cancer stem cells (CSCs) can induce recurrence and chemotherapy resistance of lung adenocarcinoma (LUAD). Reliable markers identified based on CSC characteristic of LUAD may improve patients' chemotherapy response and prognosis. OCLR was used to calculate mRNA expression-based stemness index (mRNAsi) of LUAD patients' data in TCGA. Association analysis of mRNAsi was performed with clinical features, somatic mutation, and tumor immunity. A prognostic prediction model was established with LASSO Cox regression. Kaplan-Meier Plotter (KM-plotter) and time-dependent ROC were applied to assess signature performance. For LUAD, univariate and multivariate Cox analysis was performed to identify independent prognostic factors. LUAD tissues showed a noticeably higher mRNAsi in than nontumor tissues, and it showed significant differences in T, N, M, AJCC stages, and smoking history. The most frequently mutated gene was TP53, with a higher mRNAsi relating to more frequent mutation of TP53. The mRNAsi was significantly negatively correlated with immune score, stromal score, and ESTIMATE score in LUAD. The blue module was associated with mRNAsi. The 5-gene signature was confirmed as an independent indicator of LUAD prognosis that could promote personalized treatment of LUAD and accurately predict overall survival (OS) of LUAD patients. Hindawi 2022-04-16 /pmc/articles/PMC9036162/ /pubmed/35480140 http://dx.doi.org/10.1155/2022/4404406 Text en Copyright © 2022 Renping Wan et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wan, Renping
Liao, Hongliang
Liu, Jingting
Zhou, Lin
Yin, Yingqiu
Mu, Tianhao
Wei, Jie
Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells
title Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells
title_full Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells
title_fullStr Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells
title_full_unstemmed Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells
title_short Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells
title_sort development of a 5-gene signature to evaluate lung adenocarcinoma prognosis based on the features of cancer stem cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036162/
https://www.ncbi.nlm.nih.gov/pubmed/35480140
http://dx.doi.org/10.1155/2022/4404406
work_keys_str_mv AT wanrenping developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells
AT liaohongliang developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells
AT liujingting developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells
AT zhoulin developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells
AT yinyingqiu developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells
AT mutianhao developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells
AT weijie developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells